Pfēnex: A New Biotech in Town

12/9/09

Dow Chemical has officially spun out a new San Diego-based biotech, Pfēnex, which is using a bacteria that secretes a fluorescent pigment to develop a variety of protein-based drugs, vaccines, diagnostic reagents, and biosimilars. Signet Healthcare Partners is lead investor in the venture-backed company, which is headed by CEO Bertrand C. Liang and includes a team of more than 20 scientists. Pfēnex describes its Pfēnex Expression Technology as a robust Pseudomonas fluorescens-based platform that uses high throughput and parallel processing for optimized protein production.

Bruce V. Bigelow is the editor of Xconomy San Diego. You can e-mail him at bbigelow@xconomy.com or call (619) 669-8788 Follow @

By posting a comment, you agree to our terms and conditions.